{"transactions":[{"id":4622744,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35992,"kind":"person","name":"Lynch Ryan","position":1,"cik":"0001709271","reported_name":"Lynch Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:03:34.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":240,"price":17.9,"value":4296.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":13631,"source":{"system":"sec-edgar","filing":"0001628280-26-062709","document":"wk-form4_1789761811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709271/000162828026062709/wk-form4_1789761811.xml","form_type":"4"}},{"id":4622742,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:03:19.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":658,"price":17.9,"value":11778.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 26, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":21581,"source":{"system":"sec-edgar","filing":"0001628280-26-062707","document":"wk-form4_1789761795.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000162828026062707/wk-form4_1789761795.xml","form_type":"4"}},{"id":4622738,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35929,"kind":"person","name":"Im Ellie Eunkyung","position":1,"cik":"0002075219","reported_name":"Im Ellie Eunkyung","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:59.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":623,"price":17.9,"value":11151.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":21446,"source":{"system":"sec-edgar","filing":"0001628280-26-062706","document":"wk-form4_1789761777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2075219/000162828026062706/wk-form4_1789761777.xml","form_type":"4"}},{"id":4622737,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:43.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":568,"price":17.9,"value":10167.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":19730,"source":{"system":"sec-edgar","filing":"0001628280-26-062705","document":"wk-form4_1789761760.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789545/000162828026062705/wk-form4_1789761760.xml","form_type":"4"}},{"id":4622727,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35930,"kind":"person","name":"Bispham Barbara Harlin","position":1,"cik":"0002075230","reported_name":"Bispham Barbara Harlin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:23.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":620,"price":17.9,"value":11098.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":18710,"source":{"system":"sec-edgar","filing":"0001628280-26-062703","document":"wk-form4_1789761740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2075230/000162828026062703/wk-form4_1789761740.xml","form_type":"4"}},{"id":4622729,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:05.000Z","date":"2026-09-18","kind":"sale","planned":true,"acquired":false,"shares":7837,"price":16.71,"value":130956.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":271765,"source":{"system":"sec-edgar","filing":"0001628280-26-062701","document":"wk-form4_1789761722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1528826/000162828026062701/wk-form4_1789761722.xml","form_type":"4"}},{"id":4622728,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":1610,"price":17.9,"value":28819.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":279602,"source":{"system":"sec-edgar","filing":"0001628280-26-062701","document":"wk-form4_1789761722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528826/000162828026062701/wk-form4_1789761722.xml","form_type":"4"}},{"id":4622723,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:01:44.000Z","date":"2026-09-18","kind":"sale","planned":true,"acquired":false,"shares":3839,"price":16.71,"value":64149.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":134588,"source":{"system":"sec-edgar","filing":"0001628280-26-062700","document":"wk-form4_1789761701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824673/000162828026062700/wk-form4_1789761701.xml","form_type":"4"}},{"id":4622722,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:01:44.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":731,"price":17.9,"value":13084.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":138427,"source":{"system":"sec-edgar","filing":"0001628280-26-062700","document":"wk-form4_1789761701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824673/000162828026062700/wk-form4_1789761701.xml","form_type":"4"}},{"id":705651,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-20T21:30:09.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":525897,"price":14.499,"value":7624980.603,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2294037,"derivative":{"exercise_price":0.001,"underlying":"Ordinary Shares","underlying_shares":525897},"source":{"system":"sec-edgar","filing":"0001104659-26-085113","document":"tm2620801-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/tm2620801-1_4seq1.xml","form_type":"4"}},{"id":705650,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-07-20T21:30:09.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":853450,"price":14.5,"value":12375025.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3601316,"source":{"system":"sec-edgar","filing":"0001104659-26-085113","document":"tm2620801-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/tm2620801-1_4seq1.xml","form_type":"4"}},{"id":729165,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35992,"kind":"person","name":"Lynch Ryan","position":1,"cik":"0001709271","reported_name":"Lynch Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:04:56.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":465,"price":17.99,"value":8365.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":13871,"source":{"system":"sec-edgar","filing":"0001628280-26-044893","document":"wk-form4_1782245092.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709271/000162828026044893/wk-form4_1782245092.xml","form_type":"4"}},{"id":729427,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:04:25.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1288,"price":17.99,"value":23171.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 26, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":22239,"source":{"system":"sec-edgar","filing":"0001628280-26-044892","document":"wk-form4_1782245062.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000162828026044892/wk-form4_1782245062.xml","form_type":"4"}},{"id":728738,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:03:57.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1112,"price":17.99,"value":20004.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":20298,"source":{"system":"sec-edgar","filing":"0001628280-26-044890","document":"wk-form4_1782245034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044890/wk-form4_1782245034.xml","form_type":"4"}},{"id":728736,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35930,"kind":"person","name":"Bispham Barbara Harlin","position":1,"cik":"0002075230","reported_name":"Bispham Barbara Harlin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:03:27.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1218,"price":17.99,"value":21911.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":19330,"source":{"system":"sec-edgar","filing":"0001628280-26-044887","document":"wk-form4_1782245005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044887/wk-form4_1782245005.xml","form_type":"4"}},{"id":728735,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35929,"kind":"person","name":"Im Ellie Eunkyung","position":1,"cik":"0002075219","reported_name":"Im Ellie Eunkyung","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:02:52.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1219,"price":17.99,"value":21929.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":22069,"source":{"system":"sec-edgar","filing":"0001628280-26-044886","document":"wk-form4_1782244969.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044886/wk-form4_1782244969.xml","form_type":"4"}},{"id":728733,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:02:21.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":20549,"price":17.99,"value":369676.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":139158,"source":{"system":"sec-edgar","filing":"0001628280-26-044885","document":"wk-form4_1782244938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044885/wk-form4_1782244938.xml","form_type":"4"}},{"id":728734,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:01:41.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":42305,"price":17.99,"value":761066.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":281212,"source":{"system":"sec-edgar","filing":"0001628280-26-044884","document":"wk-form4_1782244898.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044884/wk-form4_1782244898.xml","form_type":"4"}},{"id":751231,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:48:33.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040583","document":"wk-form4_1780530511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040583/wk-form4_1780530511.xml","form_type":"4"}},{"id":751230,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:48:11.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040582","document":"wk-form4_1780530489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040582/wk-form4_1780530489.xml","form_type":"4"}},{"id":752037,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30350,"kind":"person","name":"Balcom Alexandra","position":1,"cik":"0001862147","reported_name":"Balcom Alexandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:47:50.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040580","document":"wk-form4_1780530467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862147/000162828026040580/wk-form4_1780530467.xml","form_type":"4"}},{"id":751229,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41672,"kind":"person","name":"Moran Susan","position":1,"cik":"0001835225","reported_name":"Moran Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:47:11.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040577","document":"wk-form4_1780530428.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040577/wk-form4_1780530428.xml","form_type":"4"}},{"id":751228,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:46:38.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040575","document":"wk-form4_1780530395.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040575/wk-form4_1780530395.xml","form_type":"4"}},{"id":965550,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:49:10.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":70025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":70025,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":70025},"source":{"system":"sec-edgar","filing":"0001628280-25-057687","document":"wk-form4_1766008146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000162828025057687/wk-form4_1766008146.xml","form_type":"4"}},{"id":965549,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:49:10.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":22507,"source":{"system":"sec-edgar","filing":"0001628280-25-057687","document":"wk-form4_1766008146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000162828025057687/wk-form4_1766008146.xml","form_type":"4"}},{"id":965548,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:49:10.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":17507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":17507,"source":{"system":"sec-edgar","filing":"0001628280-25-057687","document":"wk-form4_1766008146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000162828025057687/wk-form4_1766008146.xml","form_type":"4"}},{"id":964665,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:46:33.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":180467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":180467,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":180467},"source":{"system":"sec-edgar","filing":"0001628280-25-057683","document":"wk-form4_1766007988.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057683/wk-form4_1766007988.xml","form_type":"4"}},{"id":964664,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:46:33.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":323517,"source":{"system":"sec-edgar","filing":"0001628280-25-057683","document":"wk-form4_1766007988.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057683/wk-form4_1766007988.xml","form_type":"4"}},{"id":964663,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:46:33.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":45117,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":313517,"source":{"system":"sec-edgar","filing":"0001628280-25-057683","document":"wk-form4_1766007988.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057683/wk-form4_1766007988.xml","form_type":"4"}},{"id":964662,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":57688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":57688,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":57688},"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":964661,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":19422,"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":964660,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":14422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":14422,"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":964659,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":78029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":78029,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":78029},"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":964658,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":159707,"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":964657,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":19507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":153707,"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":964656,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35929,"kind":"person","name":"Im Ellie Eunkyung","position":1,"cik":"0002075219","reported_name":"Im Ellie Eunkyung","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:41:09.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":65190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":65190,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":65190},"source":{"system":"sec-edgar","filing":"0001628280-25-057673","document":"wk-form4_1766007666.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057673/wk-form4_1766007666.xml","form_type":"4"}},{"id":964655,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35929,"kind":"person","name":"Im Ellie Eunkyung","position":1,"cik":"0002075219","reported_name":"Im Ellie Eunkyung","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:41:09.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":21298,"source":{"system":"sec-edgar","filing":"0001628280-25-057673","document":"wk-form4_1766007666.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057673/wk-form4_1766007666.xml","form_type":"4"}},{"id":964654,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35929,"kind":"person","name":"Im Ellie Eunkyung","position":1,"cik":"0002075219","reported_name":"Im Ellie Eunkyung","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:41:09.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":16298,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":16298,"source":{"system":"sec-edgar","filing":"0001628280-25-057673","document":"wk-form4_1766007666.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057673/wk-form4_1766007666.xml","form_type":"4"}},{"id":965082,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35992,"kind":"person","name":"Lynch Ryan","position":1,"cik":"0001709271","reported_name":"Lynch Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:38:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":33512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":33512,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":33512},"source":{"system":"sec-edgar","filing":"0001628280-25-057671","document":"wk-form4_1766007516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709271/000162828025057671/wk-form4_1766007516.xml","form_type":"4"}},{"id":965081,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35992,"kind":"person","name":"Lynch Ryan","position":1,"cik":"0001709271","reported_name":"Lynch Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:38:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":12378,"source":{"system":"sec-edgar","filing":"0001628280-25-057671","document":"wk-form4_1766007516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709271/000162828025057671/wk-form4_1766007516.xml","form_type":"4"}},{"id":965080,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35992,"kind":"person","name":"Lynch Ryan","position":1,"cik":"0001709271","reported_name":"Lynch Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:38:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":8378,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":8378,"source":{"system":"sec-edgar","filing":"0001628280-25-057671","document":"wk-form4_1766007516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709271/000162828025057671/wk-form4_1766007516.xml","form_type":"4"}},{"id":964653,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35930,"kind":"person","name":"Bispham Barbara Harlin","position":1,"cik":"0002075230","reported_name":"Bispham Barbara Harlin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:35:36.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":72185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":72185,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":72185},"source":{"system":"sec-edgar","filing":"0001628280-25-057669","document":"wk-form4_1766007333.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057669/wk-form4_1766007333.xml","form_type":"4"}},{"id":964652,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35930,"kind":"person","name":"Bispham Barbara Harlin","position":1,"cik":"0002075230","reported_name":"Bispham Barbara Harlin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:35:36.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":18422,"source":{"system":"sec-edgar","filing":"0001628280-25-057669","document":"wk-form4_1766007333.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057669/wk-form4_1766007333.xml","form_type":"4"}},{"id":964651,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35930,"kind":"person","name":"Bispham Barbara Harlin","position":1,"cik":"0002075230","reported_name":"Bispham Barbara Harlin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:35:36.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":12422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":12422,"source":{"system":"sec-edgar","filing":"0001628280-25-057669","document":"wk-form4_1766007333.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057669/wk-form4_1766007333.xml","form_type":"4"}},{"id":965546,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":71343,"kind":"person","name":"Doughty Christopher Grant","position":1,"cik":"0002074223","reported_name":"Doughty Christopher Grant","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:47:45.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":58855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":58855,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":58855},"source":{"system":"sec-edgar","filing":"0001628280-25-057685","document":"wk-form4_1766008052.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2074223/000162828025057685/wk-form4_1766008052.xml","form_type":"4"}},{"id":965545,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":71343,"kind":"person","name":"Doughty Christopher Grant","position":1,"cik":"0002074223","reported_name":"Doughty Christopher Grant","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T16:47:45.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":62194,"source":{"system":"sec-edgar","filing":"0001628280-25-057685","document":"wk-form4_1766008052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2074223/000162828025057685/wk-form4_1766008052.xml","form_type":"4"}},{"id":965544,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":71343,"kind":"person","name":"Doughty Christopher Grant","position":1,"cik":"0002074223","reported_name":"Doughty Christopher Grant","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T16:47:45.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":14714,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":54194,"source":{"system":"sec-edgar","filing":"0001628280-25-057685","document":"wk-form4_1766008052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2074223/000162828025057685/wk-form4_1766008052.xml","form_type":"4"}},{"id":974254,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T21:37:26.000Z","date":"2025-12-08","kind":"grant","planned":false,"acquired":true,"shares":172836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025."}],"balance_after":172836,"derivative":{"exercise_price":13.17,"expiration_date":"2035-12-08","underlying":"Ordinary Shares","underlying_shares":172836},"source":{"system":"sec-edgar","filing":"0001628280-25-056333","document":"wk-form4_1765402643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025056333/wk-form4_1765402643.xml","form_type":"4"}},{"id":974251,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35928,"kind":"person","name":"Brumm Joshua T","position":1,"cik":"0001528826","reported_name":"Brumm Joshua T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T21:35:41.000Z","date":"2025-12-08","kind":"grant","planned":false,"acquired":true,"shares":345672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025."}],"balance_after":345672,"derivative":{"exercise_price":13.17,"expiration_date":"2035-12-08","underlying":"Ordinary Shares","underlying_shares":345672},"source":{"system":"sec-edgar","filing":"0001628280-25-056331","document":"wk-form4_1765402538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025056331/wk-form4_1765402538.xml","form_type":"4"}},{"id":977414,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2025-12-08T21:30:15.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":131434,"price":13.409,"value":1762398.506,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1768140,"derivative":{"exercise_price":0.001,"underlying":"Ordinary Shares","underlying_shares":131434},"source":{"system":"sec-edgar","filing":"0001104659-25-119320","document":"tm2532982-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925119320/tm2532982-1_4seq1.xml","form_type":"4"}},{"id":977413,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-08T21:30:15.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":1360000,"price":13.41,"value":18237600.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2747866,"source":{"system":"sec-edgar","filing":"0001104659-25-119320","document":"tm2532982-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925119320/tm2532982-1_4seq1.xml","form_type":"4"}},{"id":1086775,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":36066,"kind":"person","name":"Pinkas Jan","position":1,"cik":"0002077126","reported_name":"Pinkas Jan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T23:11:26.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":142474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% on July 7, 2026 and in equal monthly installments thereafter through July 7, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":142474,"derivative":{"exercise_price":13.14,"expiration_date":"2035-07-16","underlying":"Ordinary Shares","underlying_shares":142474},"source":{"system":"sec-edgar","filing":"0001104659-25-068426","document":"tm2521104-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077126/000110465925068426/tm2521104-1_4seq1.xml","form_type":"4"}},{"id":1103560,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41672,"kind":"person","name":"Moran Susan","position":1,"cik":"0001835225","reported_name":"Moran Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:51:54.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061820","document":"tm2518376-18_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061820/tm2518376-18_4seq1.xml","form_type":"4"}},{"id":1103559,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:48:57.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 9,023 of the Issuer's ordinary shares, which vest in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (\"Fairmount\"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying ordinary shares. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061819","document":"tm2518376-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061819/tm2518376-17_4seq1.xml","form_type":"4"}},{"id":1103558,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:46:20.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061818","document":"tm2518376-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061818/tm2518376-15_4seq1.xml","form_type":"4"}},{"id":1103936,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30350,"kind":"person","name":"Balcom Alexandra","position":1,"cik":"0001862147","reported_name":"Balcom Alexandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:43:51.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061817","document":"tm2518376-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862147/000110465925061817/tm2518376-14_4seq1.xml","form_type":"4"}},{"id":1103557,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:41:28.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061816","document":"tm2518376-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061816/tm2518376-13_4seq1.xml","form_type":"4"}},{"id":1108869,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":25944,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":25944,"derivative":{"underlying":"Common Stock","underlying_shares":25944},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108868,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":257515,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":257515,"derivative":{"underlying":"Common Stock","underlying_shares":257515},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108867,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":304098,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":304098,"derivative":{"underlying":"Common Stock","underlying_shares":304098},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108866,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":56079,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":62383,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108865,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":556617,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":593740,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108864,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":657308,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":707116,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1437224,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-09T20:30:11.000Z","date":"2024-08-08","kind":"sale","planned":false,"acquired":false,"shares":260873,"price":0.1917,"value":50009.3541,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6317565,"source":{"system":"sec-edgar","filing":"0000950170-24-094800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024094800/ownership.xml","form_type":"4"}},{"id":1437223,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-09T20:30:11.000Z","date":"2024-08-07","kind":"sale","planned":false,"acquired":false,"shares":61488,"price":0.1821,"value":11196.9648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6578438,"source":{"system":"sec-edgar","filing":"0000950170-24-094800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024094800/ownership.xml","form_type":"4"}},{"id":1439032,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:30:11.000Z","date":"2024-08-06","kind":"sale","planned":false,"acquired":false,"shares":55732,"price":0.1828,"value":10187.8096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1907 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6639926,"source":{"system":"sec-edgar","filing":"0000950170-24-092864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024092864/ownership.xml","form_type":"4"}},{"id":1439031,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:30:11.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":164523,"price":0.1884,"value":30996.1332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.187 to $0.1891 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6695658,"source":{"system":"sec-edgar","filing":"0000950170-24-092864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024092864/ownership.xml","form_type":"4"}},{"id":1441230,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:53:26.000Z","date":"2024-08-02","kind":"sale","planned":false,"acquired":false,"shares":286200,"price":0.2004,"value":57354.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.20 to $0.2025 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6860181,"source":{"system":"sec-edgar","filing":"0000950170-24-090910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024090910/ownership.xml","form_type":"4"}},{"id":1441229,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:53:26.000Z","date":"2024-08-01","kind":"sale","planned":false,"acquired":false,"shares":63564,"price":0.2162,"value":13742.5368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.2185 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7146381,"source":{"system":"sec-edgar","filing":"0000950170-24-090910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024090910/ownership.xml","form_type":"4"}},{"id":1446491,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":756835,"price":0.2209,"value":167184.8515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 per\nshare, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon\nrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7209945,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1446490,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-29","kind":"sale","planned":false,"acquired":false,"shares":363949,"price":0.2353,"value":85637.1997,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7966780,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1446489,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-26","kind":"sale","planned":false,"acquired":false,"shares":258335,"price":0.2417,"value":62439.5695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":8330729,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1470484,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89584,"kind":"person","name":"Rock Edwin","position":1,"cik":"0001945417","reported_name":"Rock Edwin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-24T20:29:48.000Z","date":"2024-06-21","kind":"purchase","planned":false,"acquired":true,"shares":115000,"price":0.2671,"value":30716.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":680403,"source":{"system":"sec-edgar","filing":"0001415889-24-017978","document":"form4-06242024_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924017978/form4-06242024_080643.xml","form_type":"4"}},{"id":1470483,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89584,"kind":"person","name":"Rock Edwin","position":1,"cik":"0001945417","reported_name":"Rock Edwin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-24T20:29:48.000Z","date":"2024-06-20","kind":"purchase","planned":false,"acquired":true,"shares":190000,"price":0.2532,"value":48108.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":565403,"source":{"system":"sec-edgar","filing":"0001415889-24-017978","document":"form4-06242024_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924017978/form4-06242024_080643.xml","form_type":"4"}},{"id":1472922,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89711,"kind":"person","name":"Hahn Brian M.","position":1,"cik":"0001589711","reported_name":"Hahn Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance, CFO"}}],"security":"Common Stock","published_at":"2024-06-20T20:15:39.000Z","date":"2024-06-18","kind":"purchase","planned":false,"acquired":true,"shares":17500,"price":0.2477,"value":4334.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":70643,"source":{"system":"sec-edgar","filing":"0001415889-24-017623","document":"form4-06202024_040634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924017623/form4-06202024_040634.xml","form_type":"4"}},{"id":1531812,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":45754,"kind":"person","name":"Koenig Scott","position":1,"cik":"0001587514","reported_name":"Koenig Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:30:48.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011872","document":"form4-05012024_080541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011872/form4-05012024_080541.xml","form_type":"4"}},{"id":1531811,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:30:04.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011869","document":"form4-05012024_080555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011869/form4-05012024_080555.xml","form_type":"4"}},{"id":1531810,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":39174,"kind":"person","name":"PEARSON TIMOTHY R","position":1,"cik":"0001528617","reported_name":"PEARSON TIMOTHY R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:29:10.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011867","document":"form4-05012024_080504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011867/form4-05012024_080504.xml","form_type":"4"}},{"id":1531809,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":32645,"kind":"person","name":"King Rachel K.","position":1,"cik":"0001589712","reported_name":"King Rachel K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:27:06.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011863","document":"form4-05012024_080549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011863/form4-05012024_080549.xml","form_type":"4"}},{"id":1531808,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35381,"kind":"person","name":"Jackson Scott Thomas","position":1,"cik":"0001566617","reported_name":"Jackson Scott Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:25:19.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011861","document":"form4-05012024_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011861/form4-05012024_080513.xml","form_type":"4"}},{"id":1532280,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":47459,"kind":"person","name":"JUNIUS DANIEL M","position":1,"cik":"0001094159","reported_name":"JUNIUS DANIEL M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:24:33.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011860","document":"form4-05012024_080522.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094159/000141588924011860/form4-05012024_080522.xml","form_type":"4"}},{"id":1531906,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41894,"kind":"person","name":"Andrews Patricia S","position":1,"cik":"0001445710","reported_name":"Andrews Patricia S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T16:26:00.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011862","document":"form4-05012024_080551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445710/000141588924011862/form4-05012024_080551.xml","form_type":"4"}},{"id":1554552,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":47459,"kind":"person","name":"JUNIUS DANIEL M","position":1,"cik":"0001094159","reported_name":"JUNIUS DANIEL M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:05:38.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":5209,"price":3,"value":15627.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $15,625."}],"balance_after":98459,"source":{"system":"sec-edgar","filing":"0001415889-24-009745","document":"form4-04022024_040420.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094159/000141588924009745/form4-04022024_040420.xml","form_type":"4"}},{"id":1552983,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":32645,"kind":"person","name":"King Rachel K.","position":1,"cik":"0001589712","reported_name":"King Rachel K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:05:29.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":3334,"price":3,"value":10002.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000."}],"balance_after":515194,"source":{"system":"sec-edgar","filing":"0001415889-24-009743","document":"form4-04022024_040411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924009743/form4-04022024_040411.xml","form_type":"4"}},{"id":1552981,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:05:22.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":4584,"price":3,"value":13752.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":24828,"source":{"system":"sec-edgar","filing":"0001415889-24-009744","document":"form4-04022024_040413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924009744/form4-04022024_040413.xml","form_type":"4"}},{"id":1677631,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":95119,"kind":"person","name":"Johnson Bruce S","position":1,"cik":"0001971197","reported_name":"Johnson Bruce S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T21:05:28.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":3.11,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-24-001742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124001742/doc4.xml","form_type":"4"}},{"id":1677630,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89584,"kind":"person","name":"Rock Edwin","position":1,"cik":"0001945417","reported_name":"Rock Edwin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T21:05:20.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":3.11,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-24-001740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124001740/doc4.xml","form_type":"4"}},{"id":1677629,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":95118,"kind":"person","name":"Rath Chinmaya","position":1,"cik":"0001969660","reported_name":"Rath Chinmaya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T21:05:15.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":3.11,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-24-001739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124001739/doc4.xml","form_type":"4"}},{"id":1677628,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89711,"kind":"person","name":"Hahn Brian M.","position":1,"cik":"0001589711","reported_name":"Hahn Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T21:05:12.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":3.11,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-24-001738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124001738/doc4.xml","form_type":"4"}},{"id":1678003,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":76791,"kind":"person","name":"Semerjian Harout","position":1,"cik":"0001809747","reported_name":"Semerjian Harout","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T16:05:25.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":695000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date."}],"balance_after":695000,"derivative":{"exercise_price":3.11,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":695000},"source":{"system":"sec-edgar","filing":"0001209191-24-001741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809747/000120919124001741/doc4.xml","form_type":"4"}},{"id":1696208,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":32645,"kind":"person","name":"King Rachel K.","position":1,"cik":"0001589712","reported_name":"King Rachel K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-01-02T21:05:22.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":4238,"price":2.36,"value":10001.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000."}],"balance_after":511860,"source":{"system":"sec-edgar","filing":"0001209191-24-000068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124000068/doc4.xml","form_type":"4"}},{"id":1696207,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-01-02T21:05:19.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":5827,"price":2.36,"value":13751.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":20244,"source":{"system":"sec-edgar","filing":"0001209191-24-000067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124000067/doc4.xml","form_type":"4"}},{"id":1696416,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41894,"kind":"person","name":"Andrews Patricia S","position":1,"cik":"0001445710","reported_name":"Andrews Patricia S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-01-02T16:05:26.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":5191,"price":2.36,"value":12250.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $12,250."}],"balance_after":58608,"source":{"system":"sec-edgar","filing":"0001209191-24-000069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445710/000120919124000069/doc4.xml","form_type":"4"}},{"id":1766847,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-10-03T20:15:43.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":9167,"price":1.5,"value":13750.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":14417,"source":{"system":"sec-edgar","filing":"0001209191-23-051449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123051449/doc4.xml","form_type":"4"}},{"id":1766846,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":32645,"kind":"person","name":"King Rachel K.","position":1,"cik":"0001589712","reported_name":"King Rachel K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-10-03T20:05:17.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":1.5,"value":10000.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board retainer fees of $10,000."}],"balance_after":507622,"source":{"system":"sec-edgar","filing":"0001209191-23-051390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123051390/doc4.xml","form_type":"4"}},{"id":1767298,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41894,"kind":"person","name":"Andrews Patricia S","position":1,"cik":"0001445710","reported_name":"Andrews Patricia S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-10-03T16:05:33.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":8167,"price":1.5,"value":12250.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $12,250."}],"balance_after":53417,"source":{"system":"sec-edgar","filing":"0001209191-23-051392","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445710/000120919123051392/doc4.xml","form_type":"4"}},{"id":1773839,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89584,"kind":"person","name":"Rock Edwin","position":1,"cik":"0001945417","reported_name":"Rock Edwin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-25T20:21:40.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":30403,"price":1.38,"value":41956.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.37 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":375403,"source":{"system":"sec-edgar","filing":"0001209191-23-050476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123050476/doc4.xml","form_type":"4"}},{"id":1773838,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":89584,"kind":"person","name":"Rock Edwin","position":1,"cik":"0001945417","reported_name":"Rock Edwin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-25T20:21:40.000Z","date":"2023-09-21","kind":"purchase","planned":false,"acquired":true,"shares":35000,"price":1.38,"value":48300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.35 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":345000,"source":{"system":"sec-edgar","filing":"0001209191-23-050476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123050476/doc4.xml","form_type":"4"}},{"id":1869281,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":45754,"kind":"person","name":"Koenig Scott","position":1,"cik":"0001587514","reported_name":"Koenig Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-02T20:10:27.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":false,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vested on May 18, 2023 and are fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.6,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-23-033675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123033675/doc4.xml","form_type":"4"}},{"id":1869280,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":45754,"kind":"person","name":"Koenig Scott","position":1,"cik":"0001587514","reported_name":"Koenig Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T20:10:27.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":true,"shares":21000,"price":0.6,"value":12600.0,"ownership":{"direct":true},"balance_after":36750,"source":{"system":"sec-edgar","filing":"0001209191-23-033675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123033675/doc4.xml","form_type":"4"}}],"next_cursor":"2023-06-02T20:10:27.000000Z,1869280"}